Imunexus was pleased to present at the latest edition of Stocks in the Vines Investor Access Day, hosted by Mines in the Vines on 14 May 2026. The event was held in Yarra Valley, and gathered a select investor audience to hear from some of Australia's leading ASX-listed organisations across a number of different sectors.
Imunexus Executive Chair and CEO Philippa Lewis, and Chief Scientific Officer and Founder Dr George Kopsidas presented on Imunexus' unique investment opportunity, highlighting how our Imunexin™ platform is unlocking a new generation of bispecific biologics by enhancing proven drugs, accelerating development, and reducing technical risk.
In particular, Philippa and George focused on the development of their lead program, IMX39. IMX39 is a pioneering drug candidate designed to address many of the underlying aspects of multiple sclerosis (MS), and aims to provide a new approach to treatment of the disease.
Additionally, Philippa and George also touched on Imunexus' corporate strategy, our strong current and future IP position, and robust pipeline with multiple programs in development.
Designed to encourage impactful engagement in a relaxed, welcoming setting, the event allowed for compelling conversation and fostered meaningful relationships between companies, investors and industry leaders.